C17orf78

Across TCGA pan-cancer cohorts, C17orf78 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C17orf78 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher C17orf78 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C17orf78 expression acts as an unfavorable survival marker.

SKCM and PRAD are the cancer types where C17orf78 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.029	0.613	<.001	12	view →
PRAD	OS	Median	All	0.265	0.884	<.001	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C17orf78–SKCM (DFS)

Open the SKCM breakdown →